Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
| ▸ | BCL2L10 | Q9HD36 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631427 | 1.00 | BCL2L1 (0.33) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630701 | 0.89 | BCL2L1 (0.36) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630702 | 0.89 | BCL2L1 (0.36) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630928 | 0.84 | BCL2L1 (0.37) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630929 | 0.84 | BCL2L1 (0.37) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630737 | 0.82 | BCL2L1 (0.31) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630548 | 0.82 | PDPK1 (0.34) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630547 | 0.82 | PDPK1 (0.34) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL631008 | 0.78 | ITK (0.34) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL2750129 | 0.78 | CYP1A1 (0.39) | BCL2L1ASPHBCL2ADORA1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | claimed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | BCL2L1 662/4885ASPH 503/4885BCL2 129/4885 |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | ZC3HAV1, HCCS, PCNA | BCL2L1 709/4885ASPH 850/4885BCL2 267/4885 |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885ASPH 372/4885BCL2 201/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885ASPH 372/4885BCL2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.